MARKET

DMK

DMK

DMK Pharmaceuticals Corporation
NASDAQ
0.4926
-0.0171
-3.35%
Pre Market: 0.5670 +0.0744 +15.10% 08:23 11/28 EST
OPEN
0.5010
PREV CLOSE
0.5097
HIGH
0.5184
LOW
0.4926
VOLUME
189.28K
TURNOVER
0
52 WEEK HIGH
21.70
52 WEEK LOW
0.4505
MARKET CAP
4.98M
P/E (TTM)
-0.0537
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DMK last week (1120-1124)?
Weekly Report · 1d ago
Weekly Report: what happened at DMK last week (1113-1117)?
Weekly Report · 11/20 10:01
DMK Pharmaceuticals Corporation: Current report
Press release · 11/16 04:25
DMK Pharmaceuticals Corporation: Quarterly report
Press release · 11/15 19:29
DMK Pharmaceuticals GAAP EPS of -$0.20
Dmk pharmaceuticals reports q3 gaap eps of -$0.20. Cash and cash equivalents as of september 30, 2023, were approximately $6.7 million. Dmk has a market value of approximately $1.2 billion. The company posted a q3 loss of $0.16 per share.
Seeking Alpha · 11/14 12:45
DMK Pharmaceuticals Q3 EPS $(0.20) Up From $(2.05) YoY, Sales $9.06K Down From $1.51M YoY
Dmk pharmaceuticals reported quarterly losses of $0.20 per share. The company reported $9.06 million in sales for the quarter. This is a 99.40 percent decrease over sales of $1.51 million the same period last year. Dmk reported losses of 90.24 percent.
Benzinga · 11/14 12:35
DMK Pharmaceuticals Announces Presentation Of Preclinical Results Comparing Effects Of DPI-125 On Opioid Withdrawal Behaviors Versus Standard Of Care For Opioid Use Disorder At SfN Neuroscience 2023
Preclinical results compare effects of dpi-125 on opioid withdrawal behaviors to methadone and buprenorphine. Preclinical results will be presented at the society for neuroscience annual meeting in 2023. Dmk is developing a novel opioid receptor agonist for the treatment of opioid use disorder.
Benzinga · 11/13 15:53
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Senestech (nasdaq:snes) stock is rocketing more than 70% alongside heavy pre-market trading. Collective audience shares are surging over 48% without any clear news this morning. A public offering, clinical trial results and more are moving shares on monday morning. 10 top pre- market stock movers: 10 biggest gainers and losers.
Investorplace · 11/13 12:29
More
About DMK
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.

Webull offers DMK Pharmaceuticals Corp stock information, including NASDAQ: DMK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMK stock methods without spending real money on the virtual paper trading platform.